Business Context and Reporting Period
GRI Bio, Inc., a Delaware corporation, filed this Form 8-K on April 1, 2025, to report the commencement of a best efforts public offering. The company is an emerging growth company listed on the Nasdaq Capital Market under the symbol "GRI."
Key Financial Metrics and Offering Details
- Offering Structure: The offering consists of 202,000 shares of Common Stock, 1,186,888 Pre-Funded Warrants, and 4,166,664 Series E Warrants (comprising Series E-1, E-2, and E-3).
- Offering Price: $3.60 per Share with accompanying Series E Warrants; $3.5999 per Pre-Funded Warrant with accompanying Series E Warrants.
- Expected Net Proceeds: Approximately $4.2 million, after deducting placement agent fees and offering expenses.
- Warrant Terms: Series E Warrants have an exercise price of $3.20 per share. Series E-1 expires in 5 years, Series E-2 in 18 months, and Series E-3 in 9 months.
- Placement Agent Fees: H.C. Wainwright & Co., LLC will receive a 7.0% cash fee, a 1.0% management fee, a $25,000 expense allowance, up to $100,000 in legal reimbursement, and warrants to purchase 97,222 shares at $4.50 per share.
Material Changes and Liquidity Outlook
This filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The filing does not provide comparative financial metrics (revenue, profit, or cash flow) for prior periods as it is a current report on a specific transaction rather than a periodic financial statement.
Liquidity: Management believes the net proceeds from this offering, combined with existing cash and cash equivalents, will be sufficient to fund planned operations through the third quarter of 2025.
Guidance, Risks, and Management Commentary
- Use of Proceeds: Funds will be used for working capital, product candidate development, and general corporate purposes, including public company costs.
- Lock-Up Provisions: The company agreed not to issue additional equity or convertible securities for 30 days post-closing and is restricted from variable rate transactions for one year.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the completion of the offering, cash runway, and clinical development timelines. These are subject to risks including market conditions and the ability to close the offering on anticipated terms.
- Ownership Limits: Beneficial ownership limits of 4.99% or 9.99% apply to the exercise of warrants to prevent excessive concentration of ownership.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds raised, as the filing states the offering is expected to close on or about April 2, 2025.
- Confirm the exact amount of cash and cash equivalents held by the company as of the filing date to validate the "third quarter of 2025" runway estimate.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and conditions to closing.
- Monitor the exercise activity of the Series E-3 Warrants, which have the shortest expiration period (9 months).
- Check for any subsequent filings regarding the actual use of proceeds versus the stated intent.